168 related articles for article (PubMed ID: 27966431)
1. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
[TBL] [Abstract][Full Text] [Related]
2. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
4. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
6. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
Iwasa S; Yamada Y; Fukagawa T; Eguchi Nakajima T; Kato K; Hamaguchi T; Morita S; Saka M; Katai H; Shimada Y
Gastric Cancer; 2011 Mar; 14(1):28-34. PubMed ID: 21327440
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
8. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
9. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Heinrich K; Heinemann V; Stintzing S; Müller L; Ettrich TJ; Büchner-Steudel P; Geißler M; Trojan J; Moosmann N; Folprecht G; Schmidt J; Kanzler S; Kullmann F; Moulin JC; Werner J; Angele MK; Probst V; Held S; Schulz C; Boukovala M
Oncol Res Treat; 2024; 47(6):251-261. PubMed ID: 38565089
[TBL] [Abstract][Full Text] [Related]
13. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
Chou WC; Chang CL; Liu KH; Hsu JT; Cheng WH; Hsu HC; Shen WC; Hung YS; Chen JS
World J Surg Oncol; 2013 Nov; 11():287. PubMed ID: 24180462
[TBL] [Abstract][Full Text] [Related]
14. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
[TBL] [Abstract][Full Text] [Related]
15. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
17. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
[TBL] [Abstract][Full Text] [Related]
18. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim SJ; Kim YJ; Kim JH; Park DJ; Kim HH; Lee JS; Lee KW
Cancer Sci; 2013 Jan; 104(1):116-23. PubMed ID: 23066919
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
[TBL] [Abstract][Full Text] [Related]
20. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
